Home » MONOGRAM BIOSCIENCES AND MERCK TO CONDUCT ERBITUX(R) BIOMARKER STUDY
MONOGRAM BIOSCIENCES AND MERCK TO CONDUCT ERBITUX(R) BIOMARKER STUDY
Monogram Biosciences, Inc. (Nasdaq: MGRM) announced today that it has entered
into an agreement with Merck KGaA, Darmstadt, Germany (Xetra: Merck KGaA) to
conduct a cancer biomarker study with application to Erbitux(R)(cetuximab),
Merck KGaA's IgG1 monoclonal antibody specifically targeting the epidermal growth
factor receptor (EGFR) found on many cancer cells.
PR
Newswire
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May